The UK and US have signed a landmark trade agreement that will keep zero import taxes on UK medicine products going into the US market.
The Terms of the Pact
In exchange for the tariff guarantee, the UK has pledged to raise spending on drugs through the public health system. This pledge ensures that import taxes on these vital goods will be held at zero for a duration of the next three years.
This agreement follows recent warnings to dramatically increase import taxes on branded pharmaceutical products, with increases mentioned up to one hundred percent.
"This arrangement with the Britain bolsters the worldwide climate for innovative medicines and establishes long-overdue fairness to American-British drug exports," a release said.
Trade Impact
Medicines constitute one of the Britain's biggest goods shipped to the United States, which is easily the primary buyer for leading UK drugmakers.
Trade data indicate that in the year leading up to September, the UK sold medicines worth £11.1bn to the US. This value represented 17.4% of all goods exports in that span.
"This agreement secures work, increases investment and paves the way for the UK to emerge as a worldwide center for biotech and pharma," a minister remarked.
Specific NHS Changes
The agreement entails several specific changes from the United Kingdom:
- Revised Affordability Limit: The UK will raise the price threshold at which it judges new treatments to be too expensive by 25%.
- Higher Drug Budget: There is a aim to double overall NHS spending on treatments from 0.3 percent of Gross Domestic Product to 0.6% over the coming ten years.
- Rebate Cap: The percentage pharmaceutical firms must return to the NHS to stay within budget will be capped at 15%. In the past, refunds exceeded 20%.
Industry Background
This agreement follows a protracted dispute between the drug companies and the UK government over drug pricing and regulatory access.
This friction were exacerbated by arguments that US customers were charged a premium for the identical medicines than consumers in the other developed nations.
Recently, several significant manufacturing plans in the UK have been halted or cancelled, while multi-billion-dollar investments have been pledged toward US facilities.
A senior figure acknowledged that the NHS had to increase expenditure on treatments, noting that its expenditure on drugs had shrunk as a proportion of its overall budget over the previous ten-year period.
